Subscriber
Login
Access your Windhover
Publications and Databases |
| |
| Forgot
Password? |
Receive Windhover's unique market insight fast with our free alert
service 'Windhover's Update', including the latest abstracts
and summaries from:
• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight
Sign up
now
|
 |
|
|
|
 |
Upcoming
Webinars
|
|
|
New Device Conference
Medtech Insight/Windhover will host a first-of-its-kind “Medical Device Investor Day” symposium, followed immediately by their "Investment In Innovation (In3) East” conference, at The Westin Copley Place in Boston, MA, October 22-24. Both are must-attend events for medtech executives interested in what the powerhouses of the device industry are thinking, doing, and planning in terms of investment, as well as those looking to partner, invest and network with 50 of the most promising emerging device companies. Read more and register today!
|
|
|
New Conference
Windhover’s groundbreaking Pharma Business Strategies for Biomarkers will probe the strategies, dealmaking and economics of building biopharma businesses in the era of biomarkers. Read more and register today!
|
|
|
|
|
|
Another Dismal Year for New Drug Approvals
When does a drought stop being a drought, and just become a desert? FDA approved just 16 new molecular entities in 2007—the lowest single year total since 1983, when there were 14 NME approvals. Windhover’s own metric, Innovative Commercial Therapies, shows an even grimmer picture. Read more on The IN VIVO Blog.
|
|
|
|
|
|
Windhover in the News: Biogen Idec
Read Roger Longman’s comment in the December 13 issue of The New York Times about Biogen Idec’s failure to sell, and the Wall Street Journal Health Blog’s take on it. Or better yet, read our Blog post from October 17 about why Biogen Idec was unlikely to sell. |
|
|
|
From our Strategic Transactions and Publications databases |
|
|
|
|
|
|
|
|
|